Comparison Study of Oxytocin Versus Tranexamic Acid and Etamsylaye Versus Placebo(Saline)
NCT ID: NCT05273632
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2022-03-20
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate
NCT04656067
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section
NCT06010368
Determination of Blood Loss After CS
NCT04549012
Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section
NCT06060327
The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)
NCT02053922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin
Pre- Operative Oxytocin is given intravenously 5-10 minutes slowly before skin incision
Oxytocin
trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
Tranexamic acid and Etamsylate
Tranexamic acid and Etamsylate are slowly given intravenously 10 minutes before start of Cesarean Delivery
Oxytocin
trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
Saline
Normal saline (about 200 ml) is given intravenously 10 minutes before start of Cesarean Section
Oxytocin
trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age of pregnancy (38 weeks To 40 weeks).
* the average height of 145 to 160 cm,average body weight of 45 to 85 kgs.
* Singleton living fetus.
* No medical disorders.
* Informed Oral Consent From The Patient.
Exclusion Criteria
* Bleeding tendency, for example, disseminated intravascular coagulopathy, which was excluded by platelet count, coagulation time, bleeding time, prothrombin time, partial thromboplastin time, and thrombin time (all should be within normal).
* Acute liver or kidney diseases; blood disorders, such as anaemia.
* Allergy to Tranexamic acid.
* Risk factors for PPH, such as polyhydramnios, fetal macrosomia, antepartum haemorrhage.
* Ante partum Hemorrhage such placental abruption.
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Egymedicalpedia
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sayed Galal Hospital, Alhusein Hospital, Alzahraa Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EL-SAYED EL-DESOUKY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.